India Faces Higher Glargine Insulin Prices As Generics Supply Fall Short
This article was originally published in PharmAsia News
Executive Summary
India faces a shortage of locally produced glargine, the active pharmaceutical ingredient in Sanofi's Lantus insulin drug, because one of the two makers relies on importing the API from China and a supply disruption.